Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: A study by the Japanese Childhood AML Cooperative Study Group

International Journal of Hematology

Volumn 91, Issue 5, 2010, Pages 831-837

  Mizushima, Yasuhiro ^a   Taki, Tomohiko ^b   Shimada, Akira ^c   Yui, Yoshihiro ^a   Hiraumi, Yoshimi ^a   Matsubara, Hiroshi ^a   Watanabe, Motonobu ^a   Watanabe, Ken Ichiro ^a   Kamitsuji, Yuri ^d   Hayashi, Yasuhide ^c   Tsukimoto, Ichiro ^e   Kobayashi, Ryoji ^f   Horibe, Keizo ^g   Tawa, Akio ^h   Nakahata, Tatsutoshi ^a   Adachi, Souichi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c Gumna Children S Medical Center   (Japan)

^d KYOTO UNIVERSITY HOSPITAL   (Japan)

^e TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^h OSAKA NATIONAL HOSPITAL   (Japan)

Author keywords

BAALC; CEBPA; Normal karyotype; Pediatric AML

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CEBPA; UNCLASSIFIED DRUG; BAALC PROTEIN, HUMAN; CCAAT ENHANCER BINDING PROTEIN; CEBPA PROTEIN, HUMAN; ISOPROTEIN; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; BAALC TUMOR GENE; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; EXON; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; INFANT; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; NEWBORN; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PROGNOSIS; SCHOOL CHILD; TUMOR GENE; ASIAN CONTINENTAL ANCESTRY GROUP; DIAGNOSTIC USE; GENE EXPRESSION REGULATION; GENETICS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MUTATION;

ADOLESCENT; ASIAN CONTINENTAL ANCESTRY GROUP; CCAAT-ENHANCER-BINDING PROTEINS; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INFANT; INFANT, NEWBORN; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; NEOPLASM PROTEINS; PROGNOSIS; PROTEIN ISOFORMS;

EID: 77954497925     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0585-x     Document Type: Article

References (37)

1. P Brown E Mclntyre R Rau S Meshinchi N Lacayo G Dahl, et al. 2007 The incidence and clinical significance of nucleophosmin mutations in childhood AML Blood 110 979 985 10.1182/blood-2007-02-076604 1:CAS:528:DC%2BD2sXos1CqsbY%3D 17440048 (Pubitemid 47267437)
2. A Shimada T Taki K Tabuchi T Taketani R Hanada A Tawa, et al. 2008 Tandem duplications of MLL and FLT3 are correlated with poor prognosis in pediatric acute myeloid leukemia: a study of the Japanese childhood AML Cooperative Study Group Pediatr Blood Cancer 50 264 269 10.1002/pbc.21318 17763464
3. S Meshinchi TA Alonzo DL Stirewalt M Zwaan M Zimmerman D Reinhardt, et al. 2006 Clinical implications of FLT3 mutations in pediatric AML Blood 108 3654 3661 10.1182/blood-2006-03-009233 1:CAS:528:DC%2BD28Xht1Kgs77L 16912228 (Pubitemid 44864541)
4. A Shimada T Taki C Kubota A Tawa K Horibe M Tsuchida, et al. 2007 No nucleophosmin mutations in pediatric acute myeloid leukemia with normal karyotype: a study of the Japanese Childhood AML Cooperative Study Group Leukemia. 21 1307 10.1038/sj.leu.2404625 1:CAS:528:DC%2BD2sXlsFOiurg%3D 17315018 (Pubitemid 46831822)
5. SM Tanner JL Austin G Leone LJ Rush C Plass K Heinonen, et al. 2001 BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia Proc Natl Acad Sci USA 98 13901 13906 10.1073/pnas.241525498 1:CAS:528:DC%2BD3MXovVyntbo%3D 11707601 (Pubitemid 33115996)
6. CD Baldus SM Tanner AS Ruppert SP Whitman KJ Archer G Marcucci, et al. 2003 BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study Blood 102 1613 1618 10.1182/blood-2003-02-0359 1:CAS:528:DC%2BD3sXntFartb0%3D 12750167 (Pubitemid 37022550)
7. CD Baldus C Thiede S Soucek CD Bloomfield E Thiel G Ehninger, et al. 2006 BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications J Clin Oncol 24 790 797 10.1200/JCO.2005.01.6253 1:CAS:528:DC%2BD28XitVGitr0%3D 16418499 (Pubitemid 46622046)
8. G Marcucci K Mrózek CD Bloomfield 2005 Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics Curr Opin Hematol 12 68 75 10.1097/01.moh.0000149608.29685.d1 1:CAS:528:DC%2BD2MXotFequw%3D%3D 15604894 (Pubitemid 40192577)
9. K Mrózek G Marcucci P Paschka SP Whitman CD Bloomfield 2007 Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 109 431 448 10.1182/blood-2006-06- 001149 16960150 (Pubitemid 46105936)
10. CD Baldus K Mrózek G Marcucci CD Bloomfield 2007 Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review Br J Haematol 137 387 400 10.1111/j.1365-2141.2007.06566.x 1:CAS:528:DC%2BD2sXotVOhu7c%3D 17488484 (Pubitemid 46698282)
11. AF Gombart WK Hofmann S Kawano S Takeuchi U Krug SH Kwok, et al. 2002 Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein in myelodysplastic syndromes and acute myeloid leukemias Blood 99 1332 1340 10.1182/blood.V99.4.1332 1:CAS:528:DC%2BD38XhtlWqtro%3D 11830484 (Pubitemid 34547089)
12. C Preudhomme C Sagot N Boissel JM Cayuela I Tigaud S de Botton, et al. 2002 Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association Blood 100 2717 2723 10.1182/blood-2002-03-0990 1:CAS:528:DC%2BD38XotVGhsLg%3D 12351377
13. S Fröhling RF Schlenk I Stolze J Bihlmayr A Benner S Kreitmeier, et al. 2004 CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations J Clin Oncol 22 624 633 10.1200/JCO.2004.06.060 14726504 (Pubitemid 41095065)
14. J Basecke JT Whelan F Griesinger FE Bertrand 2006 The MLL partial tandem duplication in acute myeloid leukaemia Br J Haematol 135 438 449 10.1111/j.1365-2141.2006.06301.x 16965385 (Pubitemid 44583410)
15. M Bienz M Ludwig EO Leibundgut BU Mueller D Ratschiller M Solenthaler, et al. 2005 Risk assessment in patients with acute myeloid leukemia and a normal karyotype Clin Cancer Res 11 1416 1424 10.1158/1078-0432.CCR-04-1552 1:CAS:528:DC%2BD2MXhvVSrsLo%3D 15746041 (Pubitemid 40315221)
16. G Marcucci CD Baldus AS Ruppert MD Radmacher K Mrózek SP Whitman, et al. 2005 Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study J Clin Oncol 23 9234 9242 10.1200/JCO.2005.03.6137 1:CAS:528:DC%2BD28Xnt1yntg%3D%3D 16275934
17. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, van der Poel-van de Luytgaarde S, Hack R, et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood. 2003;101:837-45.
18. D Damiani M Tiribelli E Calistri A Geromin A Chiarvesio A Michelutti, et al. 2006 The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype Haematologica 91 825 828 1:CAS:528:DC%2BD28XntF2jtb4%3D 16704962
19. M Heuser G Beutel J Krauter K Döhner N von Neuhoff B Schlegelberger, et al. 2006 High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics Blood 108 3898 3905 10.1182/blood-2006-04-014845 1:CAS:528:DC%2BD28Xht1Kgs7rM 16912223 (Pubitemid 44864574)
20. MD Radmacher G Marcucci AS Ruppert K Mrózek SP Whitman JW Vardiman, et al. 2006 Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study Blood 108 1677 1683 10.1182/blood-2006-02-005538 1:CAS:528:DC%2BD28Xpt1Sltbc%3D 16670265 (Pubitemid 44316137)
21. M Yan E Kanbe LF Peterson A Boyapati Y Miao Y Wang, et al. 2006 A previous unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis Nat Med 12 945 949 10.1038/nm1443 1:CAS:528: DC%2BD28Xnsl2iurw%3D 16892037 (Pubitemid 44175147)
22. A Hossain M Nixon MT Kuo GF Saunders 2006 N-terminally truncated WT1 protein with oncogenic properties overexpressed in Leukemia J Biol Chem 281 28122 28130 10.1074/jbc.M512391200 1:CAS:528:DC%2BD28XpsFOrurY%3D 16698800 (Pubitemid 44414526)
23. JG Jurcic SD Nimer DA Scheinberg T DeBlasio RP Warrell Jr WH Miller Jr, et al. 2001 Prognostic significance of minimal residual disease and PML/RARa isoform type: long-term follow-up in acute promyelocytic leukemia Blood 98 2651 2656 10.1182/blood.V98.9.2651 1:CAS:528:DC%2BD3MXotVegsL4%3D 11675334
24. T Yagi S Hibi M Takanashi G Kano Y Tabata T Imamura, et al. 2002 High frequency of Ikaros isoform 6 expression in acute myelomonocytic and monocytic leukemias: implications for up-regulation of the antiapoptotic protein Bcl-XL in leukemogenesis Blood 99 1350 1354 10.1182/blood.V99.4.1350 1:CAS:528: DC%2BD38XhtlWqtrg%3D 11830486 (Pubitemid 34547091)
25. HW Yang HY Piao T Taki T Chen K Hashizume H Ohnishi, et al. 1999 Pattern of FHIT gene expression in normal and leukaemic cells Int J Cancer 81 897 901 10.1002/(SICI)1097-0215(19990611)81:6<897::AID-IJC10>3.0.CO;2-1 1:CAS:528:DyaK1MXktVantbk%3D 10362136 (Pubitemid 29249974)
26. A Shimada T Taki K Tabuchi A Tawa K Horibe M Tsuchida, et al. 2006 KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group Blood 107 1806 1809 10.1182/blood-2005-08-3408 1:CAS:528:DC%2BD28XitFyht7c%3D 16291592 (Pubitemid 43289357)
27. I Tsukimoto A Tawa K Horibe K Tabuchi H Kigasawa M Tsuchida, et al. 2009 Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group J Clin Oncol 27 4007 4013 10.1200/JCO.2008.18.7948 1:CAS:528:DC%2BD1MXhtFCgsbvP 19620491
28. T Pabst BU Mueller P Zhang HS Radomska S Narravula S Schnittger, et al. 2001 Dominant-negative mutations of CEBPA, encoding CCAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia Nat Genet 27 263 270 10.1038/85820 1:CAS:528:DC%2BD3MXhslOjs78%3D 11242107 (Pubitemid 32201846)
29. Najima Y, Ohashi K, Kawamura M, Onozuka Y, Yamaguchi T, Akiyama H, et al. Molecular monitoring of BAALC expression in patients with CD34-positive acute leukemia. Int J Hematol. 2010. doi: 10.1007/s12185-010-0550-8.
30. JA Robinson V Susulic YB Liu C Taylor J Hardenburg V Gironda, et al. 2006 Identification of a PTH regulated gene selectively induced in vivo during PTH-mediated bone formation J Cell Biochem 98 1203 1220 10.1002/jcb.20822 1:CAS:528:DC%2BD28XnsVyjtbo%3D 16514668 (Pubitemid 44128360)
31. AA Satoskar SM Tanner M Weinstein SJ Qualman A de la Chapelle 2005 BAALC, a marker of mesoderm and muscle Gene Expr Patterns 5 463 473 10.1016/j.modgep.2004.12.008 1:CAS:528:DC%2BD2MXhvVSmur8%3D 15749074 (Pubitemid 40331385)
32. X Wang QB Tian A Okano H Sakagami IS Moon H Kondo, et al. 2005 BAALC 1-6-8 protein is targeted to postsynaptic lipid rafts by its N-terminal myristoylation and palmitoylation, and interacts with alpha, but not beta, subunit of Ca/calmodulin-dependent protein kinase II J Neurochem 92 647 659 10.1111/j.1471-4159.2004.02902.x 1:CAS:528:DC%2BD2MXht12msb0%3D 15659234 (Pubitemid 40189467)
33. CD Baldus SM Tanner DF Kusewitt S Liyanarachchi C Choi MA Caligiuri, et al. 2003 BAALC, a novel marker of human hematopoietic progenitor cells Exp Hematol 31 1051 1056 1:CAS:528:DC%2BD3sXosVyktro%3D 14585369
34. U Bacher T Haferlach C Schoch W Kern S Schnittger 2006 Implications of NRAS mutations in AML: a study of 2502 patients Blood 107 3847 3853 10.1182/blood-2005-08-3522 1:CAS:528:DC%2BD28XkvFWhtbg%3D 16434492 (Pubitemid 43726786)
35. H Leroy C Roumier P Huyghe V Biggio P Fenaux C Preudhomme 2005 CEBPA point mutations in hematological malignancies Leukemia 19 329 334 10.1038/sj.leu.2403614 1:CAS:528:DC%2BD2MXhsFOru78%3D 15674366 (Pubitemid 40409478)
36. DC Liang LY Shih CF Huang IJ Hung CP Yang HC Liu, et al. 2005 CEBPA mutations in childhood acute myeloid leukemia Leukemia 19 410 414 10.1038/sj.leu.2403608 1:CAS:528:DC%2BD2MXhsFOrurc%3D 15618961 (Pubitemid 40403318)
37. BJ Wouters B Löwenberg CA Erpelinck-Verschueren WL van Putten PJ Valk R Delwel 2009 Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome Blood 113 3088 3091 10.1182/blood-2008-09-179895 1:CAS:528:DC%2BD1MXktFWnt74%3D 19171880